Clinical Trials Logo

Digestive System Neoplasm clinical trials

View clinical trials related to Digestive System Neoplasm.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06223230 Recruiting - Clinical trials for Digestive System Neoplasm

Nutritional Psychological Intervention and Vomit-free Management on Survival and Quality of Life in Advanced Gastrointestinal Tumors

Start date: June 1, 2022
Phase: N/A
Study type: Interventional

Aims to observe and evaluate the impact of survival and quality of life of patients with gastrointestinal tumors such as advanced esophageal, gastric, liver, pancreatic, and colorectal cancers through nutritional-psychological interventions versus no-vomit management compared to standard antitumor therapy alone

NCT ID: NCT05980416 Recruiting - Neoplasms Clinical Trials

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2

Start date: August 10, 2023
Phase: Phase 1
Study type: Interventional

This study is an open-label, international, multi-center, Phase 1 study in adult patients with solid tumors likely to express CLDN18.2.

NCT ID: NCT05238584 Recruiting - Gastric Cancer Clinical Trials

Total Versus Partial Omentectomy in the Treatment of Gastric Cancer

TOPO
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The main purpose of this study is to evaluate the role of the type of omentectomy (partial or total) in the treatment of Tis - T3 gastric cancer without serosal infiltration. The second purpose is to monitoring the blood levels of immunological factors (interleukins, T cell subtypes, etc.) pre-and postoperatively, depending on the type of omentectomy.

NCT ID: NCT04929015 Recruiting - Clinical trials for Peritoneal Carcinomatosis

Peritoneal Carcinomatosis Leveraging ctDNA Guided Treatment in GI Cancer Study (PERICLES Study)

Start date: April 29, 2021
Phase: N/A
Study type: Interventional

This clinical trial collects biospecimen samples to create a personalized ctDNA test to guide treatment for patients with gastrointestinal cancer with peritoneal carcinomatosis. Deoxyribonucleic acid, or DNA, is the material that carries all the information about how a living thing will work and function. Everyone is born with the same DNA in all our cells throughout our body. Sometimes, some of the cells in the body develop abnormalities in the DNA that cause those cells to grow abnormally and uncontrollably. Cancer occurs when there is abnormal and uncontrolled growth of cells. The DNA in cancer cells is therefore different from the DNA someone is born with. The Signatera ctDNA assay is a laboratory test that takes tumor (cancer) tissue and evaluates it for unique tumor DNA. This evaluation is used to create a report (otherwise known as an assay) personalized to each person's cancer. The personalized assay creates a personalized blood test to detect the level of abnormal DNA from the cancer that may be circulating in the body. Once this personalized blood assay is designed, it may be used to monitor a person's blood for the presence of ctDNA, which will indicate the presence or absence of cancer over time, even after treatment.

NCT ID: NCT04500990 Recruiting - Immunotherapy Clinical Trials

MRI DWI None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study

Start date: September 2020
Phase:
Study type: Observational

This is a prospective two cohorts observational study aimed to investigate the predicting value of MRI none-Gaussian model in digestive malignancies patients who received single agent PD-1/PD-L1 inhibitor or combined immunotherapy.

NCT ID: NCT04493632 Recruiting - Neoplasms Clinical Trials

OSPREY is a Post-market, Global, Multicentre, Observational, Prospective Registry.

OSPREY
Start date: April 12, 2022
Phase:
Study type: Observational [Patient Registry]

The OSPREY Patient Registry has been developed to collect and assess the performance and safety of the OncoSilâ„¢ device when used within the approved indication of unresectable, locally advanced pancreatic cancer, in combination with gemcitabine-based chemotherapy, within a real-world observational registry. The Registry data will provide both complementary and contemporary information to the existing clinical data across various countries and will form part of the post-market clinical follow-up activities for OncoSilâ„¢. Therefore, the Registry will be implemented only in countries with regulatory (commercial) approval for the OncoSilâ„¢ device.

NCT ID: NCT04133324 Recruiting - Anastomotic Leak Clinical Trials

C-protein Reactive for the Detection of Anastomotic Leakage After Surgery for Digestive Cancer

Start date: April 1, 2018
Phase:
Study type: Observational

The aim of this study is to investigate the diagnostic accuracy of the C Protein Reactive (CRP) for the detection of Anastomotic leakage after surgery for digestive cancer. The standard protocol in our unit is to measure the CRP on the second and fourth postoperative day. The main aim of the study is to investigate the diagnostic accuracy of the ratio CRP on the fourth postoperative day on CRP on the second postoperative day (CRP_D4/CRP_D2). Secondary outcomes are the diagnosis accuracy of the CRP_D4 and CRP_D2.

NCT ID: NCT04084249 Recruiting - Colorectal Cancer Clinical Trials

ctDNA-guided Surveillance for Stage III CRC, a Randomized Intervention Trial

Start date: January 1, 2020
Phase: N/A
Study type: Interventional

IMPROVE-IT2 is a randomized multicenter trial comparing the outcomes of ctDNA guided post-operative surveillance and standard-of-care CT-scan surveillance. The hypothesis of this study is that ctDNA guided post-operative surveillance combining ctDNA and radiological assessments could result in earlier detection of recurrent disease and identify more patients eligible for curative treatment.

NCT ID: NCT03978078 Recruiting - Clinical trials for Digestive System Neoplasm

A Clinicobiological Database in Metastatic Digestive Cancers

BCB-CBIO-DIG
Start date: September 12, 2016
Phase: N/A
Study type: Interventional

Creation of a collection of blood samples that will be collected before and then under treatment in patients with digestive adenocarcinoma during the 1st and 2nd metastatic line and which, depending on scientific progress, can be used for research projects aimed at developing tailored patient management strategies.